94 related articles for article (PubMed ID: 22882485)
21. Forthcoming receptor tyrosine kinase inhibitors.
Choong NW; Cohen EE
Expert Opin Ther Targets; 2006 Dec; 10(6):793-7. PubMed ID: 17105367
[TBL] [Abstract][Full Text] [Related]
22. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor.
Dudek AZ; Murthaiah PK; Franklin M; Truskinovsky AM
Acta Oncol; 2010; 49(1):101-4. PubMed ID: 19412810
[No Abstract] [Full Text] [Related]
23. Receptor tyrosine kinases as targets for anticancer therapeutics.
Carlomagno F; Santoro M
Curr Med Chem; 2005; 12(15):1773-81. PubMed ID: 16029146
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).
Nishioka C; Ikezoe T; Yang J; Yokoyama A
Leukemia; 2009 Nov; 23(11):2171-3. PubMed ID: 19657366
[No Abstract] [Full Text] [Related]
25. Multitarget drugs: the present and the future of cancer therapy.
Petrelli A; Valabrega G
Expert Opin Pharmacother; 2009 Mar; 10(4):589-600. PubMed ID: 19284362
[TBL] [Abstract][Full Text] [Related]
26. The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
Hu-Lowe D; Brega N; Patyna S
Mol Cancer Ther; 2011 Nov; 10(11):2015. PubMed ID: 22072801
[No Abstract] [Full Text] [Related]
27. [New concepts in human oncology: is it possible to use them in veterinary medicine as well?].
Marconato L; Ruess-Melzer K; Buchholz J; Kaser-Hotz B
Schweiz Arch Tierheilkd; 2011 Aug; 153(8):351-60. PubMed ID: 21780063
[TBL] [Abstract][Full Text] [Related]
28. No end in sight for telomerase-targeted cancer drugs.
Williams SC
Nat Med; 2013 Jan; 19(1):6. PubMed ID: 23295993
[No Abstract] [Full Text] [Related]
29. Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors.
Rössler J; Geoerger B; Taylor M; Vassal G
Curr Cancer Drug Targets; 2008 Feb; 8(1):76-85. PubMed ID: 18288945
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.
Gunby RH; Sala E; Tartari CJ; Puttini M; Gambacorti-Passerini C; Mologni L
Anticancer Agents Med Chem; 2007 Nov; 7(6):594-611. PubMed ID: 18045055
[TBL] [Abstract][Full Text] [Related]
31. [Targeted therapy for cancer: anti-tyrosine kinase receptor agents].
García ED
An R Acad Nac Med (Madr); 2007; 124(1):171-84; discussion 184-8. PubMed ID: 18069612
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitor special issue.
Thamm DH
Vet Comp Oncol; 2012 Sep; 10(3):161-2. PubMed ID: 22882484
[No Abstract] [Full Text] [Related]
33. Fasting plus tyrosine kinase inhibitors in cancer.
Caffa I; Longo VD; Nencioni A
Aging (Albany NY); 2015 Dec; 7(12):1026-7. PubMed ID: 26645151
[No Abstract] [Full Text] [Related]
34. [Other intracellular tyrosine kinases (including ALK)].
Mano H
Nihon Rinsho; 2012 Nov; 70 Suppl 8():52-6. PubMed ID: 23513811
[No Abstract] [Full Text] [Related]
35. [Role in oncology and targeting of the PTK7 tyrosine kinase receptor].
Ganier L; Morelli X; Borg JP
Med Sci (Paris); 2020 Oct; 36 Hors série n° 1():42-46. PubMed ID: 33052093
[No Abstract] [Full Text] [Related]
36. [Kinases and phosphatases: key enzymes in targeted cancer therapy].
Schulze M; Gohla A
Dtsch Med Wochenschr; 2013 Mar; 138(9):437-40. PubMed ID: 23423940
[No Abstract] [Full Text] [Related]
37. Veterinary oncology: Translating research advances into innovative therapeutic and diagnostic options.
Blomme EA
Vet J; 2015 Aug; 205(2):117-9. PubMed ID: 26095035
[No Abstract] [Full Text] [Related]
38. Chemotherapy safety in clinical veterinary oncology.
Klahn S
Vet Clin North Am Small Anim Pract; 2014 Sep; 44(5):941-63. PubMed ID: 25174909
[TBL] [Abstract][Full Text] [Related]
39. The discovery of receptor tyrosine kinases: targets for cancer therapy.
Gschwind A; Fischer OM; Ullrich A
Nat Rev Cancer; 2004 May; 4(5):361-70. PubMed ID: 15122207
[No Abstract] [Full Text] [Related]
40. A scheme to underpin key mediator(s) in Salinosporamide(s) against pan-tumor via systems biology concept.
Oh KK; Yoon SJ; Song SH; Park JH; Kim JS; Kim MJ; Kim DJ; Suk KT
J Transl Med; 2024 May; 22(1):492. PubMed ID: 38789990
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
